-
Featured
Immunotherapies to Treat Glioblastoma
William T. Curry, MD, co-director of Mass General Neuroscience and director of Neurosurgical Oncology in the Department of Neurosurgery at Massachusetts General Hospital, discusses a four-center trial studying the use of poliovirus to treat malignant brain tumors.
-
Concurrent Immunosuppressive Therapy With Restart of Checkpoint Inhibitor Reduces Risk of Recurrent Immune-related Enterocolitis
A retrospective study at Massachusetts General Hospital and two other centers found cancer patients who had an immune checkpoint inhibitor restarted after an episode of immune-related enterocolitis had significantly less risk of severe recurrent enterocolitis if they concurrently received infliximab or vedolizumab.
-
Review: Checkpoint Inhibitors and Other Immunotherapies in Urologic Cancer
Aleksandra Walasek, MD, and Dimitar V. Zlatev, MD, discuss progress in immunotherapies for urologic cancers, showing checkpoint inhibitors are often first-line therapy, combination regimens are improving outcomes, and antibody–drug conjugates are becoming new options for dual-refractory bladder cancer.
-
Activating CD4+ T Cells at Benign Nevi Might Prevent Melanoma
Shadmehr Demehri, MD, PhD, Erik B. Schiferle, and colleagues determined benign nevi harbor CD4+ T cells that can be activated in situ to reject the nevus. If a novel therapy could block immunosuppressive regulatory T cells, CD4+ cells might prevent progression to melanoma in high-risk patients and enhance immunotherapy.
-
Designing Leading-Edge Immunotherapy for Brain Cancer
New immunotherapy for brain cancer tackles the barrier of tumor heterogeneity using a home-grown combination of CAR T-cell therapy and bispecific antibodies.
-
Combination Checkpoint Inhibitor Therapy Safe, Extends Survival for Leptomeningeal Disease
In a phase 2 trial, researchers at the Massachusetts General Hospital Cancer Center observed that the combination of two immune checkpoint inhibitors, ipilimumab and nivolumab, was safe and associated with three-month overall survival of 44% in a heavily pretreated population of patients with leptomeningeal disease.
Mass General Cancer Center Contributors
-
Areej R. El-Jawahri, MD
Hematologist, Mass General Cancer Center, Assistant in Medicine, Massachusetts General Hospital, Instructor in Medicine, Harvard Medical School
Recent Article
Enasidenib Safe, Well Tolerated As Maintenance After Stem Cell Transplantation for IDH2-Mutated Myeloid Malignancies -
Chin-Lee Wu, MD, PhD
Director, Genitourinary Pathology Service, Massachusetts General Hospital and Mass General Cancer Center, Professor of Pathology, Harvard Medical School
Recent Article
Combined Standard and Targeted Transperineal Biopsies Advised for Patients With Prostate Lesion on Multiparametric MRI -
Justin F. Gainor, MD
Director, Center for Thoracic Cancers, Mass General Cancer Center, Director of Targeted Immunotherapy, Assistant Professor of Medicine, Harvard Medical School
Recent Article
About the Henri and Belinda Termeer Center for Targeted Therapies at the Mass General Cancer Center -
Michael L. Dougan, MD, PhD
Physician, Division of Gastroenterology, Massachusetts General Hospital, Director, GI Center for Cancer Complications, Mass General Cancer Center, Preclinical Education Group Leader, Associate Professor of Medicine, Harvard Medical School
Recent Article
Concurrent Immunosuppressive Therapy With Restart of Checkpoint Inhibitor Reduces Risk of Recurrent Immune-related Enterocolitis -
William T. Curry, MD
Co-Director, Mass General Neuroscience , Director of Neurosurgical Oncology, Massachusetts General Hospital, Adeline Rose Wydotis Professor of Neurosurgery, Harvard Medical School
Recent Article
Novel Tandem CAR T-Cell Effective Against Heterogeneous Glioblastoma